Stati Uniti - inglese - NLM (National Library of Medicine)

dispensing solutions, inc. - prednisolone (unii: 9phq9y1olm) (prednisolone - unii:9phq9y1olm) - prednisolone 15 mg in 5 ml - prednisolone oral solution is indicated in the following conditions: 1. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematos

Stati Uniti - inglese - NLM (National Library of Medicine)

proficient rx lp - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 15 mg in 5 ml - prednisolone sodium phosphate oral solution (15 mg prednisolone per 5 ml) is indicated in the following conditions: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (stevens-johnson syndrome); exfoliative erythroderma; mycosis fungoides. to induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital ad

Stati Uniti - inglese - NLM (National Library of Medicine)

physicians total care, inc. - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 15 mg in 5 ml - prednisolone sodium phosphate oral solution (15 mg prednisolone per 5 ml) is indicated in the following conditions: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (stevens-johnson syndrome); exfoliative erythroderma; mycosis fungoides. to induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephritic syndrome, without uremia. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); c

Stati Uniti - inglese - NLM (National Library of Medicine)

redpharm drug, inc. - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 15 mg in 5 ml - prednisolone sodium phosphate oral solution (15 mg prednisolone per 5 ml) is indicated in the following conditions: 1. allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. dermatologic diseases pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (stevens-johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. edematous states to induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; i

Stati Uniti - inglese - NLM (National Library of Medicine)

pharmaceutical associates, inc. - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 20 mg in 5 ml - prednisolone sodium phosphate oral solution (20 mg prednisolone base per 5 ml) is indicated in the following conditions: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (stevens-johnson syndrome); exfoliative erythroderma; mycosis fungoides. to induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenit

Stati Uniti - inglese - NLM (National Library of Medicine)

cardinal health - methylprednisolone sodium succinate (unii: lec9gky20k) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone 125 mg in 2 ml - when oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or  intramuscular use of methylprednisolone sodium succinate for injection, usp sterile powder is indicated as follows: allergic states : control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. dermatologic diseases : bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders : primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplemen

Stati Uniti - inglese - NLM (National Library of Medicine)

sagent pharmaceuticals - methylprednisolone sodium succinate (unii: lec9gky20k) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone 40 mg in 1 ml - when oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of methylprednisolone sodium succinate for injection is indicated as follows: allergic states: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. dermatologic diseases: bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particula

Francia - francese - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

zentiva france - prednisolone 20 mg sous forme de : prednisolone (métasulfobenzoate sodique de) - comprimé - 20 mg - pour un comprimé > prednisolone 20 mg sous forme de : prednisolone (métasulfobenzoate sodique de) - glucocorticoïdes - classe pharmacothérapeutique : glucocorticoides - usage systemique.code atc : h02ab06 (h. hormones non sexuelles).ce médicament est un corticoïde (également appelé anti-inflammatoire stéroïdien).indications thérapeutiques :ce médicament est réservé à l’adulte et à l’enfant de plus de 10 kg.ce médicament est utilisé dans certaines maladies, où il est utilisé pour son effet anti-inflammatoire.son action est utile dans le traitement de nombreuses affections inflammatoires ou allergiques.À fortes doses, ce médicament diminue les réactions immunitaires et est donc également utilisé pour prévenir ou traiter le rejet des greffes d’organes.

Francia - francese - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

sandoz - prednisolone 20 mg sous forme de : prednisolone (métasulfobenzoate sodique de) - comprimé - 20 mg - pour un comprimé > prednisolone 20 mg sous forme de : prednisolone (métasulfobenzoate sodique de) - glucocorticoïdes - classe pharmacothérapeutique – code atc : glucocorticoïdes, usage systémique (h : hormones non sexuelles) – h02ab06.ce médicament est un corticoïde (également appelé anti-inflammatoire stéroïdien).indications thérapeutiquesce médicament est réservé à l’adulte et à l’enfant de plus de 10 kg.ce médicament est utilisé dans certaines maladies, où il est utilisé pour son effet anti-inflammatoire.son action est utile dans le traitement de nombreuses affections inflammatoires ou allergiques.À fortes doses, ce médicament diminue les réactions immunitaires et est donc également utilisé pour prévenir ou traiter le rejet des greffes d’organes.

Francia - francese - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

viatris sante - prednisolone 20 mg sous forme de : prednisolone (métasulfobenzoate sodique de) - comprimé - 20 mg - pour un comprimé > prednisolone 20 mg sous forme de : prednisolone (métasulfobenzoate sodique de) - glucocorticoÏdes - classe pharmacothérapeutique : glucocorticoïdes - usage systémique (h : hormones non sexuelles) – code atc : h02ab06.ce médicament est un corticoïde (également appelé anti-inflammatoire stéroïdien).indications thérapeutiquesce médicament est réservé à l’adulte et à l’enfant de plus de 10 kg.ce médicament est utilisé dans certaines maladies, où il est utilisé pour son effet anti‑inflammatoire.son action est utile dans le traitement de nombreuses affections inflammatoires ou allergiques.À fortes doses, ce médicament diminue les réactions immunitaires et est donc également utilisé pour prévenir ou traiter le rejet des greffes d’organes.